Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	28.04B -2.6%
Revenue (ttm)	11.85B -0.1%
Net Income	2.14B +5.8%
EPS	2.38 +8.9%
Shares Out	887.91M
PE Ratio	14.72
Forward PE	16.64
Dividend	1.10 (3.12%)
Ex-Dividend Date	Jun 13, 2025

Volume	4,786,515
Average Volume	4,796,883
Open	34.77
Previous Close	35.31
Day's Range	34.77 - 35.32
52-Week Range	32.94 - 44.87
Beta	0.39
RSI	51.07
Earnings Date	Mar 24, 2026

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2024, SHE:000513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.